<DOC>
	<DOCNO>NCT00512135</DOCNO>
	<brief_summary>The study objective investigate safety efficacy incobotulinumtoxinA ( Xeomin ) repeat dose treatment glabellar frown line . 801 subject moderate severe glabellar frown line maximum frown complete participation one study program , i.e. , MRZ 60201-0520/1 , MRZ 60201-0527/1 , MRZ 60201-0724/1 , MRZ 60201-0741/1 eligible participate repeat-dose study .</brief_summary>
	<brief_title>Safety Efficacy IncobotulinumtoxinA ( Xeomin ) Treatment Glabellar Frown Lines</brief_title>
	<detailed_description>This prospective , multicenter , open-label , non-control group design Phase 3 clinical study . Approximately 880 subject complete former study program ( 370 subject study MRZ 60201-0520/1 ( 8 ) MRZ 60201-0527/1 ( 8 ) well approximately 510 subject study MRZ 60201-0724/1 ( 10 ) MRZ 60201-0741/1 ) ( 11 ) expect enroll study 26 center United States , Canada Germany . Subjects moderate severe glabellar frown line maximum frown complete participation one four `` feeder '' study frown line program eligible participate repeat dose study . Each subject receive dose 20 unit incobotulinumtoxinA ( Xeomin ) i.m . injection Visit 1 ( Day 0 Cycle 1 ) . Re-injections 20 U NT 201 could perform Day 0 subsequent cycle 8 cycle ( one cycle ≥ 85 day ) . Intervals treatment least three month 12 week , i.e. , ≥ 85 day . For new treatment cycle start , subject request re-injection . The investigator ass glabellar frown line relapse 'moderate ' 'severe ' . In case , new injection could administer . The treatment duration per subject 24 month eight cycle subject enrol study MRZ 60201-0520/1 MRZ 60201-0527/1 6 month two cycle subject enrol study MRZ 60201-0724/1 MRZ 60201-0741/1 , respectively . Subjects enrol study MRZ 60201-0520/1 MRZ 60201-0527/1 participate least one year study whereas subject enrol study MRZ 60201-0724/1 MRZ 60201-0741/1 participate six month two cycle .</detailed_description>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Patients 'moderate ' 'severe ' glabellar frown line maximum frown begin treatment cycle ( assessed investigator accord FWS ) , stable medical condition ; Completion one former study Merz NT 201 glabellar program Exclusion : Patients preexist neuromuscular disease ( e.g . myasthenia gravis , LambertEaton syndrome ) put patient risk , History Facial Nerve Palsy , Previous treatment Botulinum Toxin glabellar area last 12 month , Previous treatment biodegradable filler procedure ( e.g . chemical peeling , photo rejuvenation ) glabellar area last 12 month , Previous insertion permanent material glabellar area ; Planned treatment Botulinum toxin serotype body region study period , Any plan facial aesthetic procedure glabellar area trial period ; Any surgery glabellar area include surgical removal corrugator , procerus depressor supercili muscle combination scar glabellar area , Inability substantially lessen glabellar frown line even physically spread apart , Marked facial asymmetry ptosis eyelid and/or eyebrow ; Any infection area injection site .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>